{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T09:39:51Z","timestamp":1784885991093,"version":"3.55.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T00:00:00Z","timestamp":1731542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"CSCO-Qilu cancer research fund","award":["No. Y-Q201801\u2013029"],"award-info":[{"award-number":["No. Y-Q201801\u2013029"]}]},{"name":"CSCO-Qilu cancer research fund","award":["No. Y-Q201801\u2013029"],"award-info":[{"award-number":["No. Y-Q201801\u2013029"]}]},{"name":"CSCO-Qilu cancer research fund","award":["No. Y-Q201801\u2013029"],"award-info":[{"award-number":["No. Y-Q201801\u2013029"]}]},{"name":"CSCO-Qilu cancer research fund","award":["No. Y-Q201801\u2013029"],"award-info":[{"award-number":["No. Y-Q201801\u2013029"]}]},{"name":"CSCO-Qilu cancer research fund","award":["No. Y-Q201801\u2013029"],"award-info":[{"award-number":["No. Y-Q201801\u2013029"]}]},{"name":"CSCO-Qilu cancer research fund","award":["No. Y-Q201801\u2013029"],"award-info":[{"award-number":["No. Y-Q201801\u2013029"]}]},{"name":"CSCO-Qilu cancer research fund","award":["No. Y-Q201801\u2013029"],"award-info":[{"award-number":["No. Y-Q201801\u2013029"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-024-13148-y","type":"journal-article","created":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T19:08:12Z","timestamp":1731611292000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["The efficacy and safety of the prophylactic application of PEG-rhG-CSF in radiotherapy with weekly concurrent chemotherapy for cervical cancer"],"prefix":"10.1186","volume":"24","author":[{"given":"Huimin","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiming","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingchuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyuan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuxia","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,14]]},"reference":[{"issue":"2","key":"13148_CR1","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.ygyno.2017.01.033","volume":"145","author":"NR Datta","year":"2017","unstructured":"Datta NR, et al. Concurrent chemoradiotherapy vs. radiotherapy alone in locally advanced cervix cancer: a systematic review and meta-analysis. Gynecol Oncol. 2017;145(2):374\u201385.","journal-title":"Gynecol Oncol"},{"issue":"7","key":"13148_CR2","doi-asserted-by":"publisher","first-page":"2303","DOI":"10.1182\/blood.V89.7.2303","volume":"89","author":"M Mac Manus","year":"1997","unstructured":"Mac Manus M, et al. Radiotherapy-associated neutropenia and thrombocytopenia: analysis of risk factors and development of a predictive model. Blood. 1997;89(7):2303\u201310.","journal-title":"Blood"},{"key":"13148_CR3","doi-asserted-by":"crossref","unstructured":"Wang J, Li B. Chinese expert consensus on the application of pegylated recombinant human granulocyte colony-stimulating factor during concurrent chemoradiotherapy (2023 edition). Precision Radiation Oncology, 2023. 7(3): pp. 150\u2013159.","DOI":"10.1002\/pro6.1201"},{"issue":"4","key":"13148_CR4","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1269\/jrr.10103","volume":"52","author":"ZY Yu","year":"2011","unstructured":"Yu ZY, et al. RhG-CSF improves radiation-induced myelosuppression and survival in the canine exposed to fission neutron irradiation. J Radiat Res. 2011;52(4):472\u201380.","journal-title":"J Radiat Res"},{"key":"13148_CR5","doi-asserted-by":"publisher","first-page":"777602","DOI":"10.3389\/fonc.2022.777602","volume":"12","author":"W Tian","year":"2022","unstructured":"Tian W, et al. Effects of Prophylactic Administration of Granulocyte Colony-Stimulating Factor on peripheral leukocyte and neutrophil counts levels after chemotherapy in patients with early-stage breast Cancer: a retrospective cohort study. Front Oncol. 2022;12:777602.","journal-title":"Front Oncol"},{"issue":"2","key":"13148_CR6","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/S0169-5002(00)00212-9","volume":"32","author":"S Kakolyris","year":"2001","unstructured":"Kakolyris S, et al. Docetaxel in combination with gemcitabine plus rhG-CSF support as second-line treatment in non-small cell lung cancer. A multicenter phase II study. Lung Cancer. 2001;32(2):179\u201387.","journal-title":"Lung Cancer"},{"issue":"6","key":"13148_CR7","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s00280-012-1858-2","volume":"69","author":"M Asakuma","year":"2012","unstructured":"Asakuma M, et al. Phase I trial of irinotecan and amrubicin with granulocyte colony-stimulating factor support in extensive-stage small-cell lung cancer. Cancer Chemoth Pharm. 2012;69(6):1529\u201336.","journal-title":"Cancer Chemoth Pharm"},{"issue":"1","key":"13148_CR8","first-page":"702","volume":"23","author":"JF Liu","year":"2023","unstructured":"Liu JF, et al. Efficacy and safety of PEG-rhG-CSF versus rhG-CSF in preventing chemotherapy-induced-neutropenia in early-stage breast cancer patients. Thorac Cancer. 2023;23(1):702.","journal-title":"Thorac Cancer"},{"key":"13148_CR9","doi-asserted-by":"crossref","unstructured":"Sun XS et al. PEG-rhG-CSF for prophylaxis of neutropenia after chemotherapy in patients with non-small cell lung cancer: a multicenter, prospective, randomized study. 2022. 13(17): pp. 2429\u201335.","DOI":"10.1111\/1759-7714.14544"},{"issue":"1","key":"13148_CR10","first-page":"372","volume":"89","author":"X Huang","year":"2023","unstructured":"Huang X. A prospective, randomized clinical trial of emergency treatment of chemotherapy-induced neutropenia and febrile neutropenia by pegylated recombinant human granulocyte colony-stimulating factor (PEG-rhG-CSF). Breast Cancer Res Treat. 2023;89(1):372\u20139.","journal-title":"Breast Cancer Res Treat"},{"issue":"8","key":"13148_CR11","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1111\/1759-7714.13883","volume":"12","author":"J Li","year":"2021","unstructured":"Li J, et al. Safety and efficacy of administering reduced doses of pegylated recombinant human granulocyte-colony stimulating factors in patients treated with cisplatin and etoposide for small cell carcinoma: a retrospective study. Thorac Cancer. 2021;12(8):1154\u201361.","journal-title":"Thorac Cancer"},{"key":"13148_CR12","doi-asserted-by":"crossref","unstructured":"Zou D, Guo M, Zhou Q. A clinical study of pegylated recombinant human granulocyte colony stimulating factor (PEG-rhG-CSF) in preventing neutropenia during concurrent chemoradiotherapy of cervical cancer. 2021. 21(1): p. 661.","DOI":"10.1186\/s12885-021-08364-9"},{"issue":"3","key":"13148_CR13","doi-asserted-by":"publisher","first-page":"761","DOI":"10.3892\/etm.2014.2160","volume":"9","author":"FP Wu","year":"2015","unstructured":"Wu FP, et al. Clinical observation of the therapeutic effects of pegylated recombinant human granulocyte colony-stimulating factor in patients with concurrent chemoradiotherapy-induced grade IV neutropenia. Exp Ther Med. 2015;9(3):761\u20135.","journal-title":"Exp Ther Med"},{"issue":"2","key":"13148_CR14","first-page":"310","volume":"23","author":"W Li","year":"2023","unstructured":"Li W, et al. Efficacy and safety of PEG-rhG-CSF in preventing chemoradiotherapy-induced neutropenia in patients with locally advanced cervical cancer. Biomol Biomed. 2023;23(2):310\u20136.","journal-title":"Biomol Biomed"},{"key":"13148_CR15","doi-asserted-by":"crossref","unstructured":"Bongiovanni A et al. Clinical role of filgrastim in the management of patients at risk of prolonged severe neutropenia: an evidence-based review. 2019. 73(11): p. e13404.","DOI":"10.1111\/ijcp.13404"},{"issue":"3","key":"13148_CR16","doi-asserted-by":"publisher","first-page":"175","DOI":"10.2165\/00063030-200923030-00004","volume":"23","author":"W Renwick","year":"2009","unstructured":"Renwick W, Pettengell R, Green M. Use of filgrastim and pegfilgrastim to support delivery of chemotherapy: twenty years of clinical experience. BioDrugs. 2009;23(3):175\u201386.","journal-title":"BioDrugs"},{"issue":"2","key":"13148_CR17","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1007\/s00520-014-2457-z","volume":"23","author":"AM Pfeil","year":"2015","unstructured":"Pfeil AM, et al. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review. Support Care Cancer. 2015;23(2):525\u201345.","journal-title":"Support Care Cancer"},{"issue":"4","key":"13148_CR18","first-page":"495","volume":"25","author":"YK Shi","year":"2006","unstructured":"Shi YK, et al. [Phase I clinical trail of intravenous pegylated recombinant human granulocyte colony-stimulating factor]. Ai Zheng. 2006;25(4):495\u2013500.","journal-title":"Ai Zheng"},{"key":"13148_CR19","unstructured":"Cheng S et al. [Clinical Observation of pegylated Recombinant Human Granulocyte Colony Stimulating Factor for revention of Neutropenia During Concurrent Chemoradiotherapy for Cervical Cancer]. Anti-tumor Pharmacy, 2022. 12(4): pp. 503\u2013507."},{"issue":"5","key":"13148_CR20","doi-asserted-by":"publisher","first-page":"790","DOI":"10.4103\/jcrt.JCRT_320_17","volume":"13","author":"F Liu","year":"2017","unstructured":"Liu F, et al. A clinical study of polyethylene glycol recombinant human granulocyte colony-stimulating factor prevention neutropenia syndrome in patients with esophageal carcinoma and lung cancer after concurrent chemoradiotherapy. J Cancer Res Ther. 2017;13(5):790\u20135.","journal-title":"J Cancer Res Ther"},{"issue":"7","key":"13148_CR21","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1007\/s00520-014-2555-y","volume":"23","author":"G Kourlaba","year":"2015","unstructured":"Kourlaba G, et al. Comparison of filgrastim and pegfilgrastim to prevent neutropenia and maintain dose intensity of adjuvant chemotherapy in patients with breast cancer. Support Care Cancer. 2015;23(7):2045\u201351.","journal-title":"Support Care Cancer"},{"issue":"3","key":"13148_CR22","doi-asserted-by":"publisher","first-page":"562","DOI":"10.1016\/j.ijrobp.2013.01.037","volume":"86","author":"N Shaverdian","year":"2013","unstructured":"Shaverdian N, et al. Effects of Treatment Duration during Concomitant Chemoradiation Therapy for Cervical Cancer. Int J Radiation Oncology*Biology*Physics. 2013;86(3):562\u20138.","journal-title":"Int J Radiation Oncology*Biology*Physics"},{"issue":"3","key":"13148_CR23","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/cpdd.819","volume":"10","author":"C Hu","year":"2021","unstructured":"Hu C, et al. Pharmacokinetics and pharmacodynamics of two formulations of pegylated recombinant human granulocyte colony-stimulating factor in healthy Chinese subjects: an Open-Label, Randomized, parallel-design bioavailability study. Clin Pharmacol Drug Dev. 2021;10(3):291\u20138.","journal-title":"Clin Pharmacol Drug Dev"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13148-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-024-13148-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-024-13148-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,14]],"date-time":"2024-11-14T20:02:18Z","timestamp":1731614538000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-024-13148-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,14]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["13148"],"URL":"https:\/\/doi.org\/10.1186\/s12885-024-13148-y","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,14]]},"assertion":[{"value":"14 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Medical Ethics Committee of the Affiliated Cancer Hospital of Zhengzhou University (No. 2019221). All patients signed informed consent forms.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The study received written informed consent for publication by all patients.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1405"}}